Dynavax Technologies Corp. (NASDAQ:DVAX) shares were up 4.7% on Friday . The company traded as high as $15.00 and last traded at $14.90, with a volume of 340,288 shares trading hands. The stock had previously closed at $14.23.

A number of research analysts recently weighed in on DVAX shares. Cowen and Company restated a “buy” rating and set a $60.00 target price on shares of Dynavax Technologies Corp. in a research note on Thursday, April 28th. Zacks Investment Research upgraded shares of Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research note on Wednesday, May 25th. JPMorgan Chase & Co. cut shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $29.00 to $22.00 in a research note on Wednesday, April 27th. Finally, Royal Bank Of Canada cut shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $48.00 to $17.00 in a research note on Wednesday, April 27th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Dynavax Technologies Corp. has an average rating of “Hold” and an average target price of $32.20.

The firm’s market cap is $573.58 million. The firm has a 50 day moving average price of $15.10 and a 200-day moving average price of $18.54.

Dynavax Technologies Corp. (NASDAQ:DVAX) last released its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.07. The firm had revenue of $942 million for the quarter, compared to analysts’ expectations of $627 million. Analysts anticipate that Dynavax Technologies Corp. will post ($2.90) earnings per share for the current year.

In other news, CEO Eddie Gray purchased 2,750 shares of the stock in a transaction that occurred on Friday, May 20th. The shares were purchased at an average cost of $15.57 per share, with a total value of $42,817.50. Following the completion of the acquisition, the chief executive officer now owns 5,050 shares of the company’s stock, valued at approximately $78,628.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

A number of hedge funds have recently made changes to their positions in DVAX. Swiss National Bank increased its stake in shares of Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the period. Trexquant Investment LP increased its stake in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares during the period. Alps Advisors Inc. purchased a new stake in shares of Dynavax Technologies Corp. during the fourth quarter worth about $1,223,000. Finally, California State Teachers Retirement System increased its stake in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares during the period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.